Brandon L. McClellan

University of Michigan — United States

Medicine · Health Sciences

9h-index571citations21works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(10), Immunotherapy and Immune Responses(5), Immune cells in cancer(5), Epigenetics and DNA Methylation(3), Autophagy in Disease and Therapy(3)

Publications21 total

Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy
2025
Autophagy Upregulation in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma Uncovers a Novel Therapeutic Target
2025Open Access
Peripheral blood mononuclear cell (PBMC)- based functional evaluation of human T cell response to suppressive cells and immune-oncology therapeutics
Methods in cell biology·2025
Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry
Current Protocols·2025· 1 citedOpen Access
TMIC-79. IDH1-R132H REWIRES AUTOPHAGY IN THE GLIOMA MICROENVIRONMENT TO FACILITATE TUMOR PROGRESSION AND RESPONSE TO RADIATION
Neuro-Oncology·2024· 1 citedOpen Access
CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection
2024· 3 citedOpen Access
Epigenetic Reprogramming of Autophagy Leads to Uncovering a Novel Therapeutic Target for Mutant IDH1 Astrocytomas
2024· 3 citedOpen Access
IMMU-19. MUTANT ISOCITRATE DEHYDROGENASE 1 IN GLIOMA CAUSES A REDUCTION IN ADENOSINERGIC PATHWAY SIGNALING WITHIN THE TUMOR MICROENVIRONMENT
Neuro-Oncology·2023Open Access
Miniaturized microarray-format digital ELISA enabled by lithographic protein patterning
Biosensors and Bioelectronics·2023· 23 citedOpen Access
H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas
2023· 6 citedOpen Access
Impact of epigenetic reprogramming on antitumor immune responses in glioma
Journal of Clinical Investigation·2023· 60 citedOpen Access
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
Frontiers in Medicine·2022· 28 citedOpen Access
Systemic Delivery of an Adjuvant CXCR4–CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy
ACS Nano·2022· 133 citedOpen Access
Murine brain tumor microenvironment immunophenotyping using mass cytometry
STAR Protocols·2022· 2 citedOpen Access
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy
Science Advances·2021· 87 citedOpen Access
Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy
2021· 1 citedOpen Access
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
Frontiers in Oncology·2021· 23 citedOpen Access
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Frontiers in Pharmacology·2021· 84 citedOpen Access
Current Approaches for Glioma Gene Therapy and Virotherapy
Frontiers in Molecular Neuroscience·2021· 91 citedOpen Access
Extrafollicular CD4 T cell-derived IL-10 functions rapidly and transiently to support anti-Plasmodium humoral immunity
PLoS Pathogens·2021· 25 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

María G. Castro(17), Mahmoud S. Alghamri(14), Pedro R. Löwenstein(14), Kaushik Banerjee(13), Anzar Mujeeb(10), Stephen V. Carney(9), Syed Mohd Faisal(9), Andrea Comba(8), Felipe J. Núñez(8), Ayman Taher(7), Padma Kadiyala(7), Ziwen Zhu(7), María L. Varela(6), Santiago Haase(6), María Belén Garcia-Fabiani(6), Rohit Thalla(5), Joerg Lahann(5), Claire E. Tronrud(5), Anna Schwendeman(4), Marianela Candolfi(4)